Professor Sir Rory Collins
- Mexico City Prospective Study
- UK Biobank
- ATLAS: International ATLAS (Adjuvant Tamoxifen Longer Against Shorter) Breast Cancer Treatment Trial
- HPS: Heart Protection Study
- HPS2 -THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events
- HPS3 / TIMI 55 - REVEAL : Randomised EValuation of the Effects of Anacetrapib through Lipid-modification
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- ATT: Antithrombotic Trialists' Collaboration
- CTT: Cholesterol Treatment Trialists' Collaboration
- EBCTCG: Early Breast Cancer Trialists' Collaborative Group
- Trials Methodology
- Research Regulation
- Oxford Cholesterol Study
Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology
Rory Collins studied Medicine at St Thomas’s Hospital Medical School, London University (1974-1980), and Statistics at George Washington University (1976-7) and at Oxford University (1982-3).
In 1985 he became co-director, with Professor Sir Richard Peto, of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation.
He became Principal Investigator and Chief Executive of the UK Biobank prospective study of 500,000 people in September 2005. From July 2013, he became the Head of the Nuffield Department of Population Health at Oxford University.
His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer. He was knighted in 2011 for his services to science.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C. et al, (2005), Lancet, 366, 1267 - 1278
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Antithrombotic Trialists' Collaboration None., (2002), BMJ, 324, 71 - 86
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22
Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study
Herrington, WG. et al, (2018), Lancet Diabetes and Endocrinology
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Aung T. et al, (2018), JAMA Cardiol, 3, 225 - 234
Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke.
Holmes MV. et al, (2018), J Am Coll Cardiol, 71, 620 - 632
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Hopewell JC. et al, (2018), European Heart Journal
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Parish S. et al, (2018), Circ Genom Precis Med, 11